← Back to Search

Cognitive Remediation

SCORES for Schizophrenia Risk (SCORES Trial)

N/A
Recruiting
Led By Barbara A Cornblatt, Ph.D.
Research Sponsored by Northwell Health
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be younger than 65 years old
Must not have
Significant visual or auditory impairment
Estimated IQ<70
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline, mid-treatment (5 weeks), post treatment (10 weeks)
Awards & highlights

Summary

This trial tests the SCORES program, which uses brain training and group support to help adolescents at risk for psychosis. The program aims to improve thinking speed and social skills through engaging exercises and support.

Who is the study for?
This trial is for adolescents showing early signs of psychosis, specifically those who have certain symptoms but haven't been diagnosed with a schizophrenia-spectrum disorder. Participants should be English speakers without significant neurological issues, intellectual disability (IQ<70), major head injury, or severe sensory impairments.
What is being tested?
The SCORES program aims to improve processing speed and social functioning over 10 weeks through cognitive exercises and group support. It's designed for young people at risk of developing schizophrenia or other psychotic disorders and is delivered remotely.
What are the potential side effects?
Since SCORES involves cognitive training and support groups rather than medication, typical drug side effects are not expected. However, participants may experience fatigue or stress from the exercises or emotional discomfort during group discussions.

Eligibility Criteria

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I have major issues with my sight or hearing.
Select...
My IQ is estimated to be below 70.
Select...
I have been diagnosed with a schizophrenia-spectrum disorder.
Select...
I have a history of significant brain or nerve disorders.
Select...
I do not speak English.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline, mid-treatment (5 weeks), post treatment (10 weeks)
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline, mid-treatment (5 weeks), post treatment (10 weeks) for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Processing Speed domain score from the MATRICS Consensus Cognitive Battery (MCCB)
Secondary study objectives
Global Functioning: Social (GF:Social) scale (Phase 2/R33 only)
SIPS/SOPS: Positive Symptoms (Phase 2/R33 only)

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Speeded Cognitive TrainingExperimental Treatment1 Intervention
Participants in this condition will complete 40 hours of Cognitive Remediation with a mid-point assessment (20 hours/5 weeks) to determine the impact of speeded cognitive training tasks on cognition and social function.
Group II: Non-Speeded Cognitive TrainingActive Control1 Intervention
Participants in this condition will complete 40 hours of Cognitive Remediation with a mid-point assessment (20 hours/5 weeks) to determine the impact of non-speeded cognitive training tasks on cognition and social function.

Research Highlights

Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.
Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
Common treatments for prodromal symptoms, such as those studied in the SCORES trial, involve cognitive training exercises and group support. Cognitive training exercises target specific cognitive deficits like processing speed, which is essential for improving social functioning and daily task management. Group support aims to enhance motivation and engagement, providing a supportive environment that encourages treatment adherence and social interaction. These mechanisms are vital for prodromal symptoms patients as they address both cognitive and social challenges, potentially preventing the progression to full-blown psychosis.
Cognitive Remediation as an Adjunct Treatment for Substance Use Disorders: A Systematic Review.The effects of cognitive remediation on cognitive abilities and real-world functioning among people with bipolar disorder: A systematic review: Special Section on "Translational and Neuroscience Studies in Affective Disorders". Section Editor, Maria Nobile MD, PhD. This Section of JAD focuses on the relevance of translational and neuroscience studies in providing a better understanding of the neural basis of affective disorders. The main aim is to briefly summaries relevant research findings in clinical neuroscience with particular regards to specific innovative topics in mood and anxiety disorders.Computerised training improves cognitive performance in chronic pain: a participant-blinded randomised active-controlled trial with remote supervision.

Find a Location

Who is running the clinical trial?

National Institute of Mental Health (NIMH)NIH
2,869 Previous Clinical Trials
2,777,482 Total Patients Enrolled
2 Trials studying Prodromal Symptoms
274 Patients Enrolled for Prodromal Symptoms
Northwell HealthLead Sponsor
473 Previous Clinical Trials
472,218 Total Patients Enrolled
Barbara A Cornblatt, Ph.D.Principal InvestigatorNorthwell Health

Media Library

SCORES (Cognitive Remediation) Clinical Trial Eligibility Overview. Trial Name: NCT05131035 — N/A
Prodromal Symptoms Research Study Groups: Speeded Cognitive Training, Non-Speeded Cognitive Training
Prodromal Symptoms Clinical Trial 2023: SCORES Highlights & Side Effects. Trial Name: NCT05131035 — N/A
SCORES (Cognitive Remediation) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05131035 — N/A
~20 spots leftby May 2026